Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Axcella Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11309
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Axcella Health Inc (Axcella), formerly Pronutria Biosciences Inc is a developer of disease-specific amino acid profiles. The company’s lead clinical-stage candidates AXA are based on cell-specific sets of amino acids that regulate multiple biological pathways. Its amino acid therapies helps in treating orphan diseases in muscle, neurological, metabolic and liver settings, which include myotonic dystrophy, intractable epilepsy syndromes, pediatric nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, sarcopenia and other disease populations. Axcella conducts human signal seeking and confirming studies to understand the impact of various AXA candidates on human liver biology. The company uses a proprietary platform to identify the amino acid profile associated with a medical condition and de-risk the clinical development process. Axcella is headquartered in Cambridge, Massachusetts, the US.

Axcella Health Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Axcella Health Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
Partnerships 15
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Equity Offering 16
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc – Key Competitors 17
Axcella Health Inc – Key Employees 18
Axcella Health Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Oct 22, 2018: Axcella appoints Stephen Mitchener, PharmD, to senior vice president, chief business officer 20
Jun 27, 2018: Axcella Welcomes William D. Baird, and Cristina M. Rondinone to Board of Directors 21
May 31, 2018: Axcella Health Names Bill Hinshaw as President and Chief Executive Officer 23
Jan 03, 2018: Axcella Announces Appointment of David Epstein, Former CEO of Novartis Pharmaceuticals, as Chairman of its Board of Directors 24
Sep 14, 2017: Axcella Appoints Manu Chakravarthy, M.D., Ph.D., as Chief Medical Officer 25
Jun 14, 2017: Axcella Appoints Tony Tramontin, Ph.D., as Senior Vice President, Chief Scientific Officer 26
May 11, 2017: Axcella Announces the Appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., as Executive Vice President, Chief Strategy and Corporate Development Officer 27
Jan 03, 2017: Axcella Augments Leadership Team with the Appointment of Three Key Hires 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Axcella Health Inc, Pharmaceuticals & Healthcare, Key Facts 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc, Key Competitors 17
Axcella Health Inc, Key Employees 18

List of Figures
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Helm AG:戦略・SWOT・企業財務分析
    Helm AG - Strategy, SWOT and Corporate Finance Report Summary Helm AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Bukwang Pharmaceutical Co Ltd (003000):企業の財務・戦略的SWOT分析
    Summary Bukwang Pharmaceutical Co Ltd (Bukwang Pharmaceutical) is a pharmaceutical company that develops new drugs and pharmaceutical products. The company’s products portfolio includes dexide, chioctaside, levovir, orfil, lonacene, axima, and excel, among others. Its pipeline products comprise JM-0 …
  • PPL Corporation (PPL):石油・ガス:M&Aディール及び事業提携情報
    Summary PPL Corp (PPL) is an energy holding company. Through its subsidiaries, LG&E, Kentucky Utilities, and KU Energy, it generates, transmits, distributes, and sells electricity; and distributes and sells natural gas. The company produces electricity from coal, natural gas, oil, hydro, and solar s …
  • China Datang Corp:電力:M&Aディール及び事業提携情報
    Summary China Datang Corp (CDT) is engaged in development, investment, construction, operation and management of power generation assets. The company provides electric power equipment, environment protection device, memory card and card reader; religion crafts, meter for electricity, safety products …
  • Pakistan Water and Power Development Authority:発電所・企業SWOT分析
    Pakistan Water and Power Development Authority - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, i …
  • Shenzhen Kaifa Technology Co Ltd (000021):企業の財務・戦略的SWOT分析
    Shenzhen Kaifa Technology Co Ltd (000021) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • High Arctic Energy Services Inc (HWO):企業の財務・戦略的SWOT分析
    Summary High Arctic Energy Services Inc (High Arctic) operates as an oil and gas company that provides drilling services and equipment for rentals. The company provides services such as drilling services, matting and equipment rentals, snubbing services and nitrogen services. It offers equipment ren …
  • Hanwei Energy Services Corp (HE):企業の財務・戦略的SWOT分析
    Summary Hanwei Energy Services Corp (Hanwei Energy) is a chemical company that develops, manufactures and distributes plastic fibre reinforced piping systems. The company’s products include anhydride and amine cured frp pipes, fittings, fixtures and flanges. It offers client solutions such as pre-te …
  • EpiVax Inc-製薬・医療分野:企業M&A・提携分析
    Summary EpiVax Inc (EpiVax) is an immunology company which develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear se …
  • Debiopharm Group:製薬・医療:M&Aディール及び事業提携情報
    Summary Debiopharm Group (Debiopharm) is a biopharmaceutical company that develops biologics and small molecule drug candidates. The company’s product portfolio includes eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also of …
  • Guangzhou Improve Medical Instruments Co Ltd (300030):医療機器:M&Aディール及び事業提携情報
    Summary Guangzhou Improve Medical Instruments Co Ltd (Improve Medical) is a medical devices company that offers medical products, technologies, and services for clinical laboratory and clinical nursing. The company’s products include Improvacuter evacuated blood collection systems, Impromini capilla …
  • Exact Sciences Corp (EXAS):企業の製品パイプライン分析2018
    Summary Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the early detection and prevention of various types of cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the …
  • Bionomics Ltd (BNO):企業の財務・戦略的SWOT分析
    Summary Bionomics Ltd (Bionomics) is a biopharmaceutical company that discovers and develops treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer's disease. The company provides pipeline products such as BNC210, BNC 105, BNC101 and BNC375, among other …
  • IntegraGen SA (ALINT):企業の財務・戦略的SWOT分析
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • ReNeuron Group Plc (RENE):企業の財務・戦略的SWOT分析
    ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • TESARO Inc (TSRO):医療機器:M&Aディール及び事業提携情報
    Summary TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The co …
  • UCB Inc-製薬・医療分野:企業M&A・提携分析
    Summary UCB Inc (UCB), a subsidiary of UCB SA is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, metad …
  • Mission Pharmacal Company:企業の戦略・SWOT・財務情報
    Mission Pharmacal Company - Strategy, SWOT and Corporate Finance Report Summary Mission Pharmacal Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Bank Audi SAL:企業の戦略・SWOT・財務分析
    Bank Audi SAL - Strategy, SWOT and Corporate Finance Report Summary Bank Audi SAL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Total E&P Canada Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Total E&P Canada Ltd (Total E&P Canada), a subsidiary of Total S.A. is an oil and gas company that offers exploration and production of oil and gas properties. The company has assets in Alberta’s Athabasca Oil Sands region, which include Surmont, Northern Lights, Fort Hills and Joslyn North …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆